A Phase 4 interventional study of Gel containing a Propionibacterium extract and Hyaluronic acid and silver sulfadiazine in Anus Diseases, Gastrointestinal Diseases and Intestinal Diseases, sponsored by University of Cagliari. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-02.
Sponsored by University of Cagliari · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Hemorrhoids with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Hemorrhoids · Italy.
Among the 15 studies in Hemorrhoids with a site in Italy, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 3 in phase 4, and was the 12th registered.
240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.
Browse Hemorrhoids studies →3 of the 15 studies in Hemorrhoids with a site in Italy are open now. Recruiting first, the newest first:
Cardarelli Hospital · Sites in Italy
Ages 18–75
Treviso Regional Hospital · Sites in Italy
Ages 18–85
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
This study's enrollment of 114 is above the median of 100 across 185 interventional studies indexed under Hemorrhoids.
Median enrollment 105 across the 11 interventional studies, 90 across the 4 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of Cagliari has 1 study filed under Hemorrhoids — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Hemorrhoids with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter randomized controlled phase IV trial aims to compare the clinical efficacy of a gel containing a Propionibacterium extract and a gel with hyaluronic acid and silver sulfadiazine in the degree of epithelialization of post-operative wounds of open excisional hemorrhoidectomy.
The main questions it aims to answer are:
240 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.
This study's enrollment of 114 is above the median of 100 across 185 interventional studies indexed under Hemorrhoids.
Browse Hemorrhoids studies →University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
Compared within Hemorrhoids, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Gastrointestinal Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Gel containing a Propionibacterium extract
Drug: Hyaluronic acid and silver sulfadiazine
Patients will apply 1 ml of gel (equal to one phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
Drug pages: Hyaluronic AcidStudies of Hyaluronic AcidHyaluronic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Silver SulfadiazineStudies of Silver SulfadiazineSilver Sulfadiazine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will apply 1ml of gel (equal to a phalanx) twice a day for 20 days, manually at the anal level and in the perianal area. In the morning, after defecation and in the evening before going to bed.
Degree of epithelialization
The degree of epithelialization of the fissure was determined at each visit and stratified using 3 levels (1 to 3) corresponding to: 1. \< 50% 2. \> 50% 3. 100% (complete healing)
Time frame: From baseline to visit 3 (40 days after the start of the treatment)
Burning and pain
Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)
Time frame: From baseline to visit 3 (40 days after the start of the treatment)
Itching
Visual analogue scale (VAS) (minimum score = 0, maximum score = 10)
Time frame: From baseline to visit 3 (40 days after the start of the treatment)
Bowel movements
Bristol Scale (minimum score =1, maximum score =7)
Time frame: At visit 3 (40 days after the start of the treatment)
Plan to share: No
Ran from Mar 2025 to primary completion in Mar 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cagliari